Pharmacoinformatics-based identification of potential bioactive compounds against Ebola virus protein VP24. - Samuel K. Kwofie; Emmanuel Broni; Joshua Teye; Erasmus Quansah; Ibrahim Issah; Michael D. Wilson; Whelton A. Miller III; Elvis K. Tiburu; Joseph H. K. Bonney (Comput. Biol. Medicine, 2019)

Molecular docking and dynamics simulations studies of OmpATb identifies four potential novel natural product-derived anti-Mycobacterium tuberculosis compounds. - Samuel K. Kwofie; Courage Adobor; Erasmus Quansah; Joana Bentil; Michael Ampadu; Whelton A. Miller III; Michael D. Wilson (Comput. Biol. Medicine, 2020)

Pharmacophore-Guided Identification of Natural Products as Potential Inhibitors of Mycobacterium ulcerans Cystathionine γ-Synthase MetB. - Samuel K. Kwofie; Nigel N. O. Dolling; Emmanuel Donkoh; Godwin M. Laryea; Lydia Mosi; Whelton A. Miller III; Michael B. Adinortey; Michael D. Wilson (Comput., 2021)

Design of Inhibitors That Target the Menin-Mixed-Lineage Leukemia Interaction. - Moses N. Arthur; Kristeen Bebla; Emmanuel Broni; Carolyn Ashley; Miriam Velazquez; Xianin Hua; Ravi Radhakrishnan; Samuel K. Kwofie; Whelton A. Miller III (Comput., 2024)

Structure-Based Discovery of Potential HPV E6 and EBNA1 Inhibitors: Implications for Cervical Cancer Treatment. - Emmanuel Broni; Carolyn Ashley; Miriam Velazquez; Patrick O. Sakyi; Samuel K. Kwofie; Whelton A. Miller III (Comput., 2024)